Advertisement

Timing and necessity of staging imaging in clinical stage II cutaneous melanoma: Cost-effectiveness and clinical decision analysis

Published:October 14, 2022DOI:https://doi.org/10.1016/j.amjsurg.2022.10.022

      Highlights

      • Routine preoperative imaging in clinical stage II melanoma is not recommended.
      • It is still frequently obtained in practice, despite being low yield and costly.
      • Selective postoperative imaging is a more cost-effective approach.
      • Lymphovascular invasion was associated with occult metastases in this population.

      Abstract

      Background

      Preoperative imaging in clinical stage II melanoma is not indicated per National Comprehensive Cancer Network (NCCN) guidelines but remains common in clinical practice.

      Methods

      Patients presenting with cutaneous clinical stage II melanoma from 2007 to 2019 were retrospectively reviewed. A clinical decision analysis with cost data was designed to understand ideal practice patterns in managing stage II melanoma, with pre-versus selective post-operative imaging as the initial decision node.

      Results

      There were 277 subjects included, and 143 underwent preoperative imaging (49.5%). This changed management (i.e. no surgery) in one patient (0.4%). Overall, 16 patients had additional findings on imaging (5.8%). Upfront surgery with selective postoperative imaging was a more cost-effective strategy than routine performance of preoperative imaging, with savings of $1677 per patient.

      Conclusion

      Preoperative imaging is a low yield, costly approach for patients with clinical stage II melanoma with minimal impact on the decision to proceed with surgical management.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Coit D.G.
        • Thompson J.A.
        • Albertini M.R.
        • et al.
        Cutaneous melanoma, version 2.2019, NCCN clinical practice guidelines in Oncology.
        J Natl Compr Cancer Netw. 2019; 17: 367-402https://doi.org/10.6004/jnccn.2019.0018
        • Sondak V.K.
        • Gibney G.T.
        Surgical management of melanoma.
        Hematol Oncol Clin N Am. 2014; 28: 455-470https://doi.org/10.1016/j.hoc.2014.02.009
        • Karapetyan L.
        • Kirkwood J.M.
        State of melanoma: an historic overview of a field in transition.
        Hematol Oncol Clin N Am. 2021; 35: 1-27https://doi.org/10.1016/j.hoc.2020.09.003
        • Leiter U.
        • Meier F.
        • Schittek B.
        • Garbe C.
        The natural course of cutaneous melanoma.
        J Surg Oncol. 2004; 86: 172-178https://doi.org/10.1002/jso.20079
        • Schadendorf D.
        • van Akkooi A.C.J.
        • Berking C.
        • et al.
        Melanoma [published correction appears in Lancet.
        Lancet. 2018; 392 (2019 Feb 23;393(10173):746]): 971-984https://doi.org/10.1016/S0140-6736(18)31559-9
        • Laks S.
        • Meyers M.O.
        • Deal A.M.
        • et al.
        Tumor mitotic rate and association with recurrence in sentinel lymph node negative stage II melanoma patients.
        Am Surg. 2017; 83: 972-978https://doi.org/10.1177/000313481708300934
        • Liu J.
        • Blake S.J.
        • Yong M.C.
        • et al.
        Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease.
        Cancer Discov. 2016; 6: 1382-1399https://doi.org/10.1158/2159-8290.CD-16-0577
        • Rozeman E.A.
        • Menzies A.M.
        • van Akkooi A.C.J.
        • et al.
        Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
        Lancet Oncol. 2019; 20: 948-960https://doi.org/10.1016/S1470-2045(19)30151-2
        • Goepfert R.P.
        • Myers J.N.
        • Gershenwald J.E.
        Updates in the evidence-based management of cutaneous melanoma.
        Head Neck. 2020; 42: 3396-3404https://doi.org/10.1002/hed.26398
        • Gershenwald J.E.
        • Scolyer R.A.
        • Hess K.R.
        • et al.
        Melanoma of the skin.
        in: Amin M.B. AJCC Cancer Staging Manual. eighth ed. Springer, Switzerland2017: 563-585
        • Harris P.A.
        • Taylor R.
        • Thielke R.
        • Payne J.
        • Gonzalez N.
        • Conde J.G.
        Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.
        J Biomed Inf. 2009; 42: 377-381https://doi.org/10.1016/j.jbi.2008.08.010
        • Harris P.A.
        • Taylor R.
        • Minor B.L.
        • et al.
        The REDCap consortium: building an international community of software platform partners.
        J Biomed Inf. 2019; 95103208https://doi.org/10.1016/j.jbi.2019.103208
        • Faries M.B.
        • Thompson J.F.
        • Cochran A.J.
        • et al.
        Completion dissection or observation for sentinel-node metastasis in melanoma.
        N Engl J Med. 2017; 376: 2211-2222https://doi.org/10.1056/NEJMoa1613210
        • Garbe C.
        • Hauschild A.
        • Volkenandt M.
        • et al.
        Evidence and interdisciplinary consensus-based German guidelines: diagnosis and surveillance of melanoma.
        Melanoma Res. 2007; 17: 393-399https://doi.org/10.1097/CMR.0b013e3282f05039
        • Michielin O.
        • van Akkooi A.C.J.
        • Ascierto P.A.
        • Dummer R.
        • Keilholz U.
        • ESMO Guidelines Committee
        Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2019; 30: 1884-1901https://doi.org/10.1093/annonc/mdz411
        • Garbe C.
        • Amaral T.
        • Peris K.
        • et al.
        European consensus-based interdisciplinary guideline for melanoma. Part 1: diagnostics - Update 2019.
        Eur J Cancer. 2020; 126 (10.1016/j.ejca.2019.11.014): 141-158https://doi.org/10.1016/j.ejca.2019.11.014
        • Society of Surgical Oncology
        Five things physicians and patients should question.
        Choosing Wisely. 2016;
        • Cassel C.K.
        • Guest J.A.
        Choosing wisely: helping physicians and patients make smart decisions about their care.
        JAMA. 2012; 307: 1801-1802https://doi.org/10.1001/jama.2012.476
        • Brooks W.C.
        • Votanopoulos K.I.
        • Russell G.B.
        • Shen P.
        • Levine E.A.
        Evaluation of chest radiographs and laboratory testing during melanoma staging procedures.
        Am Surg. 2019; 85: 505-510https://doi.org/10.1177/000313481908500528
        • Wang T.S.
        • Johnson T.M.
        • Cascade P.N.
        • Redman B.G.
        • Sondak V.K.
        • Schwartz J.L.
        Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma.
        J Am Acad Dermatol. 2004; 51: 399-405https://doi.org/10.1016/j.jaad.2004.02.017
        • Yancovitz M.
        • Finelt N.
        • Warycha M.A.
        • et al.
        Role of radiologic imaging at the time of initial diagnosis of stage T1b-T3b melanoma.
        Cancer. 2007; 110: 1107-1114https://doi.org/10.1002/cncr.22868
        • Ascierto P.A.
        • Del Vecchio M.
        • Mandalá M.
        • et al.
        Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial [published correction appears in Lancet Oncol.
        Lancet Oncol. 2020; 21 (2021 Oct;22(10):e428]): 1465-1477https://doi.org/10.1016/S1470-2045(20)30494-0
        • Dummer R.
        • Brase J.C.
        • Garrett J.
        • et al.
        Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial.
        Lancet Oncol. 2020; 21: 358-372https://doi.org/10.1016/S1470-2045(20)30062-0
        • Robert C.
        • Ribas A.
        • Schachter J.
        • et al.
        Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.
        Lancet Oncol. 2019; 20: 1239-1251https://doi.org/10.1016/S1470-2045(19)30388-2
        • Luke J.J.
        • Rutkowski P.
        • Queirolo P.
        • et al.
        Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
        Lancet. 2022; 399: 1718-1729https://doi.org/10.1016/S0140-6736(22)00562-1
        • Niakosari F.
        • Kahn H.J.
        • McCready D.
        • et al.
        Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
        Arch Dermatol. 2008; 144: 462-467
        • Paek S.C.
        • Griffith K.A.
        • Johnson T.M.
        • et al.
        The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma.
        Cancer. 2007; 109: 100-108https://doi.org/10.1002/cncr.22382
        • Han D.
        • Zager J.S.
        • Shyr Y.
        • et al.
        Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma.
        J Clin Oncol. 2013; 31: 4387-4393https://doi.org/10.1200/JCO.2013.50.1114